1	8	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Complications	_	_	NNS	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	LVADs	_	_	NNS	_	_	_	_	_


1	While	_	_	IN	_	_	_	_	_
2	survival	_	_	NN	_	_	_	_	_
3	has	_	_	VBZ	_	_	_	_	_
4	improved	_	_	VBN	_	_	_	_	_
5	with	_	_	IN	_	_	_	_	_
6	CF-LVADS	_	_	NNP	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	adverse	_	_	JJ	_	_	_	_	_
10	event	_	_	NN	_	_	_	_	_
11	profile	_	_	NN	_	_	_	_	_
12	remains	_	_	VBZ	_	_	_	_	_
13	high	_	_	JJ	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	At	_	_	IN	_	_	_	_	_
2	1	_	_	CD	_	_	_	_	_
3	month	_	_	NN	_	_	_	_	_
4	post-implant	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	nearly	_	_	RB	_	_	_	_	_
7	30	_	_	CD	_	_	_	_	_
8	%	_	_	NN	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	at	_	_	IN	_	_	_	_	_
11	1	_	_	CD	_	_	_	_	_
12	year	_	_	NN	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	almost	_	_	RB	_	_	_	_	_
15	80	_	_	CD	_	_	_	_	_
16	%	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	patients	_	_	NNS	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	require	_	_	VBP	_	_	_	_	_
21	readmission	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	common	_	_	JJ	_	_	_	_	_
3	LVAD-related	_	_	JJ	_	_	_	_	_
4	complications	_	_	NNS	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	outside	_	_	IN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	immediate	_	_	JJ	_	_	_	_	_
10	post-operative	_	_	JJ	_	_	_	_	_
11	period	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	are	_	_	VBP	_	_	_	_	_
14	outlined	_	_	VBN	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	Table	_	_	NNP	_	_	_	_	_
17	4	_	_	CD	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	Providers	_	_	NNS	_	_	_	_	_
2	in	_	_	IN	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	community	_	_	NN	_	_	_	_	_
5	may	_	_	MD	_	_	_	_	_
6	be	_	_	VB	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	first	_	_	JJ	_	_	_	_	_
9	medical	_	_	JJ	_	_	_	_	_
10	contact	_	_	NN	_	_	_	_	_
11	for	_	_	IN	_	_	_	_	_
12	patients	_	_	NNS	_	_	_	_	_
13	with	_	_	IN	_	_	_	_	_
14	LVADs	_	_	NNS	_	_	_	_	_
15	experiencing	_	_	VBG	_	_	_	_	_
16	a	_	_	DT	_	_	_	_	_
17	complication	_	_	NN	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	Though	_	_	IN	_	_	_	_	_
2	management	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	these	_	_	DT	_	_	_	_	_
5	complications	_	_	NNS	_	_	_	_	_
6	should	_	_	MD	_	_	_	_	_
7	be	_	_	VB	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	concert	_	_	NN	_	_	_	_	_
10	with	_	_	IN	_	_	_	_	_
11	LVAD	_	_	NN	_	_	_	_	_
12	specialists	_	_	NNS	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	an	_	_	DT	_	_	_	_	_
15	awareness	_	_	NN	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	understanding	_	_	NN	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	common	_	_	JJ	_	_	_	_	_
21	complications	_	_	NNS	_	_	_	_	_
22	can	_	_	MD	_	_	_	_	_
23	help	_	_	VB	_	_	_	_	_
24	with	_	_	IN	_	_	_	_	_
25	timely	_	_	JJ	_	_	_	_	_
26	diagnosis	_	_	NN	_	_	_	_	_
27	and	_	_	CC	_	_	_	_	_
28	therapeutic	_	_	JJ	_	_	_	_	_
29	intervention	_	_	NN	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	8.1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	LVAD	_	_	NNP	_	_	_	_	_


1	Infections	_	_	NNS	_	_	_	_	_


1	Due	_	_	JJ	_	_	_	_	_
2	to	_	_	TO	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	presence	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	a	_	_	DT	_	_	_	_	_
7	percutaneous	_	_	JJ	_	_	_	_	_
8	driveline	_	_	NN	_	_	_	_	_
9	exiting	_	_	VBG	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	skin	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	infections	_	_	NNS	_	_	_	_	_
14	remain	_	_	VBP	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	Achilles	_	_	NNP	_	_	_	_	_
17	heel	_	_	NN	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	LVADs	_	_	NNP	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	Recent	_	_	JJ	_	_	_	_	_
2	implantation	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	first-in-man	_	_	NN	_	_	_	_	_
6	totally	_	_	RB	_	_	_	_	_
7	implantable	_	_	JJ	_	_	_	_	_
8	LVAD	_	_	NN	_	_	_	_	_
9	aims	_	_	VBZ	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	minimize	_	_	VB	_	_	_	_	_
12	this	_	_	DT	_	_	_	_	_
13	risk	_	_	NN	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	ISHLT	_	_	NNP	_	_	_	_	_
2	classifies	_	_	VBZ	_	_	_	_	_
3	infections	_	_	NNS	_	_	_	_	_
4	in	_	_	IN	_	_	_	_	_
5	LVAD	_	_	NN	_	_	_	_	_
6	patients	_	_	NNS	_	_	_	_	_
7	as	_	_	IN	_	_	_	_	_
8	VAD-specific	_	_	JJ	_	_	_	_	_
9	(	_	_	-LRB-	_	_	_	_	_
10	involving	_	_	VBG	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	pump	_	_	NN	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	cannula	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	pocket	_	_	NN	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	or	_	_	CC	_	_	_	_	_
19	percutaneous	_	_	JJ	_	_	_	_	_
20	driveline	_	_	NN	_	_	_	_	_
21	)	_	_	-RRB-	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	VAD-related	_	_	JJ	_	_	_	_	_
24	(	_	_	-LRB-	_	_	_	_	_
25	infective	_	_	JJ	_	_	_	_	_
26	endocarditis	_	_	NN	_	_	_	_	_
27	,	_	_	,	_	_	_	_	_
28	blood	_	_	NN	_	_	_	_	_
29	stream	_	_	NN	_	_	_	_	_
30	infections	_	_	NNS	_	_	_	_	_
31	including	_	_	VBG	_	_	_	_	_
32	central	_	_	JJ	_	_	_	_	_
33	venous	_	_	JJ	_	_	_	_	_
34	catheter	_	_	NN	_	_	_	_	_
35	associated	_	_	VBN	_	_	_	_	_
36	,	_	_	,	_	_	_	_	_
37	mediastinitis	_	_	NN	_	_	_	_	_
38	)	_	_	-RRB-	_	_	_	_	_
39	and	_	_	CC	_	_	_	_	_
40	non-VAD	_	_	JJ	_	_	_	_	_
41	infections	_	_	NNS	_	_	_	_	_
42	such	_	_	JJ	_	_	_	_	_
43	as	_	_	IN	_	_	_	_	_
44	pneumonia	_	_	NN	_	_	_	_	_
45	.	_	_	.	_	_	_	_	_


1	Different	_	_	JJ	_	_	_	_	_
2	techniques	_	_	NNS	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	largely	_	_	RB	_	_	_	_	_
5	limited	_	_	VBN	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	single-center	_	_	JJ	_	_	_	_	_
8	experiences	_	_	NNS	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	have	_	_	VBP	_	_	_	_	_
11	been	_	_	VBN	_	_	_	_	_
12	shown	_	_	VBN	_	_	_	_	_
13	to	_	_	TO	_	_	_	_	_
14	reduce	_	_	VB	_	_	_	_	_
15	infection	_	_	NN	_	_	_	_	_
16	rates	_	_	NNS	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	there	_	_	EX	_	_	_	_	_
19	is	_	_	VBZ	_	_	_	_	_
20	no	_	_	DT	_	_	_	_	_
21	universal	_	_	JJ	_	_	_	_	_
22	protocol	_	_	NN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	Risk	_	_	NN	_	_	_	_	_
2	factors	_	_	NNS	_	_	_	_	_
3	for	_	_	IN	_	_	_	_	_
4	driveline	_	_	NN	_	_	_	_	_
5	infection	_	_	NN	_	_	_	_	_
6	include	_	_	VBP	_	_	_	_	_
7	trauma	_	_	NN	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	driveline	_	_	NN	_	_	_	_	_
11	exit	_	_	NN	_	_	_	_	_
12	site	_	_	NN	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	younger	_	_	JJR	_	_	_	_	_
15	age	_	_	NN	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	higher	_	_	JJR	_	_	_	_	_
18	body	_	_	NN	_	_	_	_	_
19	mass	_	_	NN	_	_	_	_	_
20	index	_	_	NN	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	exposed	_	_	VBN	_	_	_	_	_
23	driveline	_	_	NN	_	_	_	_	_
24	velour	_	_	NN	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	Meticulous	_	_	JJ	_	_	_	_	_
2	exit	_	_	NN	_	_	_	_	_
3	site	_	_	NN	_	_	_	_	_
4	and	_	_	CC	_	_	_	_	_
5	driveline	_	_	NN	_	_	_	_	_
6	care	_	_	NN	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	driveline	_	_	NN	_	_	_	_	_
9	immobilization	_	_	NN	_	_	_	_	_
10	are	_	_	VBP	_	_	_	_	_
11	advised	_	_	VBN	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	reduce	_	_	VB	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	risk	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	infection	_	_	NN	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	Driveline	_	_	NN	_	_	_	_	_
2	drainage	_	_	NN	_	_	_	_	_
3	culture	_	_	NN	_	_	_	_	_
4	and	_	_	CC	_	_	_	_	_
5	blood	_	_	NN	_	_	_	_	_
6	cultures	_	_	NNS	_	_	_	_	_
7	should	_	_	MD	_	_	_	_	_
8	be	_	_	VB	_	_	_	_	_
9	obtained	_	_	VBN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	imaging	_	_	NN	_	_	_	_	_
13	may	_	_	MD	_	_	_	_	_
14	be	_	_	VB	_	_	_	_	_
15	needed	_	_	VBN	_	_	_	_	_
16	as	_	_	RB	_	_	_	_	_
17	well	_	_	RB	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	important	_	_	JJ	_	_	_	_	_
4	to	_	_	TO	_	_	_	_	_
5	note	_	_	VB	_	_	_	_	_
6	that	_	_	IN	_	_	_	_	_
7	driveline	_	_	NN	_	_	_	_	_
8	site	_	_	NN	_	_	_	_	_
9	assessment	_	_	NN	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	obtaining	_	_	VBG	_	_	_	_	_
12	specimens	_	_	NNS	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	drainage	_	_	NN	_	_	_	_	_
16	should	_	_	MD	_	_	_	_	_
17	only	_	_	RB	_	_	_	_	_
18	be	_	_	VB	_	_	_	_	_
19	performed	_	_	VBN	_	_	_	_	_
20	by	_	_	IN	_	_	_	_	_
21	members	_	_	NNS	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	the	_	_	DT	_	_	_	_	_
24	LVAD	_	_	NNP	_	_	_	_	_
25	team	_	_	NN	_	_	_	_	_
26	(	_	_	-LRB-	_	_	_	_	_
27	or	_	_	CC	_	_	_	_	_
28	designated	_	_	VBN	_	_	_	_	_
29	shared	_	_	VBN	_	_	_	_	_
30	care	_	_	NN	_	_	_	_	_
31	centers	_	_	NNS	_	_	_	_	_
32	)	_	_	-RRB-	_	_	_	_	_
33	in	_	_	IN	_	_	_	_	_
34	order	_	_	NN	_	_	_	_	_
35	to	_	_	TO	_	_	_	_	_
36	limit	_	_	VB	_	_	_	_	_
37	the	_	_	DT	_	_	_	_	_
38	number	_	_	NN	_	_	_	_	_
39	of	_	_	IN	_	_	_	_	_
40	times	_	_	NNS	_	_	_	_	_
41	and	_	_	CC	_	_	_	_	_
42	the	_	_	DT	_	_	_	_	_
43	number	_	_	NN	_	_	_	_	_
44	of	_	_	IN	_	_	_	_	_
45	people	_	_	NNS	_	_	_	_	_
46	to	_	_	TO	_	_	_	_	_
47	whom	_	_	WP	_	_	_	_	_
48	the	_	_	DT	_	_	_	_	_
49	driveline	_	_	NN	_	_	_	_	_
50	is	_	_	VBZ	_	_	_	_	_
51	exposed	_	_	VBN	_	_	_	_	_
52	.	_	_	.	_	_	_	_	_


1	Culture	_	_	NN	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	any	_	_	DT	_	_	_	_	_
4	drainage	_	_	NN	_	_	_	_	_
5	is	_	_	VBZ	_	_	_	_	_
6	recommended	_	_	VBN	_	_	_	_	_
7	.	_	_	.	_	_	_	_	_


1	Abnormal	_	_	JJ	_	_	_	_	_
2	swelling	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	region	_	_	NN	_	_	_	_	_
6	surrounding	_	_	VBG	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	driveline	_	_	NN	_	_	_	_	_
9	site	_	_	NN	_	_	_	_	_
10	should	_	_	MD	_	_	_	_	_
11	be	_	_	VB	_	_	_	_	_
12	assessed	_	_	VBN	_	_	_	_	_
13	by	_	_	IN	_	_	_	_	_
14	imaging	_	_	VBG	_	_	_	_	_
15	studies	_	_	NNS	_	_	_	_	_
16	(	_	_	-LRB-	_	_	_	_	_
17	i.	_	_	FW	_	_	_	_	_
18	e.	_	_	FW	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	ultrasound	_	_	NN	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	CT	_	_	NN	_	_	_	_	_
23	scan	_	_	NN	_	_	_	_	_
24	or	_	_	CC	_	_	_	_	_
25	PET	_	_	NN	_	_	_	_	_
26	scan	_	_	NN	_	_	_	_	_
27	)	_	_	-RRB-	_	_	_	_	_
28	to	_	_	TO	_	_	_	_	_
29	assess	_	_	VB	_	_	_	_	_
30	the	_	_	DT	_	_	_	_	_
31	presence	_	_	NN	_	_	_	_	_
32	,	_	_	,	_	_	_	_	_
33	extent	_	_	NN	_	_	_	_	_
34	,	_	_	,	_	_	_	_	_
35	and	_	_	CC	_	_	_	_	_
36	appearance	_	_	NN	_	_	_	_	_
37	of	_	_	IN	_	_	_	_	_
38	any	_	_	DT	_	_	_	_	_
39	fluid	_	_	JJ	_	_	_	_	_
40	collections	_	_	NNS	_	_	_	_	_
41	.	_	_	.	_	_	_	_	_


1	Blood	_	_	NN	_	_	_	_	_
2	cultures	_	_	NNS	_	_	_	_	_
3	are	_	_	VBP	_	_	_	_	_
4	important	_	_	JJ	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	evaluate	_	_	VB	_	_	_	_	_
7	for	_	_	IN	_	_	_	_	_
8	occult	_	_	JJ	_	_	_	_	_
9	bloodstream	_	_	NN	_	_	_	_	_
10	infections	_	_	NNS	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	because	_	_	IN	_	_	_	_	_
13	LVAD	_	_	NN	_	_	_	_	_
14	patients	_	_	NNS	_	_	_	_	_
15	may	_	_	MD	_	_	_	_	_
16	not	_	_	RB	_	_	_	_	_
17	present	_	_	VB	_	_	_	_	_
18	with	_	_	IN	_	_	_	_	_
19	typical	_	_	JJ	_	_	_	_	_
20	signs	_	_	NNS	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	symptoms	_	_	NNS	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	Typical	_	_	JJ	_	_	_	_	_
2	pathogens	_	_	NNS	_	_	_	_	_
3	are	_	_	VBP	_	_	_	_	_
4	skin	_	_	NN	_	_	_	_	_
5	flora	_	_	NN	_	_	_	_	_
6	like	_	_	IN	_	_	_	_	_
7	coagulase-negative	_	_	JJ	_	_	_	_	_
8	Staphylococci	_	_	NN	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	Staphylococcus	_	_	NNP	_	_	_	_	_
11	aureus	_	_	NN	_	_	_	_	_
12	.	_	_	.	_	_	_	_	_


1	Gram-negative	_	_	JJ	_	_	_	_	_
2	organisms	_	_	NNS	_	_	_	_	_
3	like	_	_	IN	_	_	_	_	_
4	Pseudomonas	_	_	NNP	_	_	_	_	_
5	spp.	_	_	NNS	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	Enterobacteriaceae	_	_	NNP	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	fungal	_	_	JJ	_	_	_	_	_
11	infections	_	_	NNS	_	_	_	_	_
12	can	_	_	MD	_	_	_	_	_
13	also	_	_	RB	_	_	_	_	_
14	occur	_	_	VB	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	Surgical	_	_	JJ	_	_	_	_	_
2	evaluation	_	_	NN	_	_	_	_	_
3	for	_	_	IN	_	_	_	_	_
4	debridement	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	driveline	_	_	NN	_	_	_	_	_
8	exit	_	_	NN	_	_	_	_	_
9	site	_	_	NN	_	_	_	_	_
10	may	_	_	MD	_	_	_	_	_
11	be	_	_	VB	_	_	_	_	_
12	needed	_	_	VBN	_	_	_	_	_
13	depending	_	_	VBG	_	_	_	_	_
14	on	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	extent	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	infection	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	should	_	_	MD	_	_	_	_	_
23	be	_	_	VB	_	_	_	_	_
24	performed	_	_	VBN	_	_	_	_	_
25	by	_	_	IN	_	_	_	_	_
26	a	_	_	DT	_	_	_	_	_
27	surgical	_	_	JJ	_	_	_	_	_
28	team	_	_	NN	_	_	_	_	_
29	with	_	_	IN	_	_	_	_	_
30	LVAD	_	_	NN	_	_	_	_	_
31	experience	_	_	NN	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	Infectious	_	_	JJ	_	_	_	_	_
2	diseases	_	_	NNS	_	_	_	_	_
3	consultation	_	_	NN	_	_	_	_	_
4	may	_	_	MD	_	_	_	_	_
5	be	_	_	VB	_	_	_	_	_
6	needed	_	_	VBN	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	particularly	_	_	RB	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	case	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	polymicrobial	_	_	JJ	_	_	_	_	_
14	infections	_	_	NNS	_	_	_	_	_
15	or	_	_	CC	_	_	_	_	_
16	multidrug-resistant	_	_	JJ	_	_	_	_	_
17	organisms	_	_	NNS	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	If	_	_	IN	_	_	_	_	_
2	bacteremia	_	_	NN	_	_	_	_	_
3	or	_	_	CC	_	_	_	_	_
4	sepsis	_	_	NN	_	_	_	_	_
5	are	_	_	VBP	_	_	_	_	_
6	present	_	_	JJ	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	a	_	_	DT	_	_	_	_	_
9	chest	_	_	NN	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	abdomen	_	_	NN	_	_	_	_	_
12	CT	_	_	NN	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	transthoracic	_	_	JJ	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	even	_	_	RB	_	_	_	_	_
17	transesophageal	_	_	JJ	_	_	_	_	_
18	echocardiogram	_	_	NN	_	_	_	_	_
19	should	_	_	MD	_	_	_	_	_
20	be	_	_	VB	_	_	_	_	_
21	obtained	_	_	VBN	_	_	_	_	_
22	to	_	_	TO	_	_	_	_	_
23	evaluate	_	_	VB	_	_	_	_	_
24	for	_	_	IN	_	_	_	_	_
25	the	_	_	DT	_	_	_	_	_
26	source	_	_	NN	_	_	_	_	_
27	of	_	_	IN	_	_	_	_	_
28	the	_	_	DT	_	_	_	_	_
29	infection	_	_	NN	_	_	_	_	_
30	(	_	_	-LRB-	_	_	_	_	_
31	especially	_	_	RB	_	_	_	_	_
32	in	_	_	IN	_	_	_	_	_
33	patients	_	_	NNS	_	_	_	_	_
34	with	_	_	IN	_	_	_	_	_
35	pacemaker	_	_	NN	_	_	_	_	_
36	or	_	_	CC	_	_	_	_	_
37	defibrillator	_	_	NN	_	_	_	_	_
38	leads	_	_	NNS	_	_	_	_	_
39	)	_	_	-RRB-	_	_	_	_	_
40	.	_	_	.	_	_	_	_	_


1	There	_	_	EX	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	an	_	_	DT	_	_	_	_	_
4	emerging	_	_	VBG	_	_	_	_	_
5	role	_	_	NN	_	_	_	_	_
6	for	_	_	IN	_	_	_	_	_
7	PET	_	_	NN	_	_	_	_	_
8	imaging	_	_	NN	_	_	_	_	_
9	with	_	_	IN	_	_	_	_	_
10	F-18	_	_	NNP	_	_	_	_	_
11	labeled	_	_	VBN	_	_	_	_	_
12	fluoro-2-deoxyglucose	_	_	NN	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	VAD	_	_	NN	_	_	_	_	_
2	infections	_	_	NNS	_	_	_	_	_
3	are	_	_	VBP	_	_	_	_	_
4	biofilm-based	_	_	JJ	_	_	_	_	_
5	and	_	_	CC	_	_	_	_	_
6	difficult	_	_	JJ	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	eradicate	_	_	VB	_	_	_	_	_
9	.	_	_	.	_	_	_	_	_


1	Treatment	_	_	NN	_	_	_	_	_
2	strategies	_	_	NNS	_	_	_	_	_
3	for	_	_	IN	_	_	_	_	_
4	VAD	_	_	NN	_	_	_	_	_
5	infections	_	_	NNS	_	_	_	_	_
6	include	_	_	VBP	_	_	_	_	_
7	intravenous	_	_	JJ	_	_	_	_	_
8	antibiotics	_	_	NNS	_	_	_	_	_
9	followed	_	_	VBN	_	_	_	_	_
10	by	_	_	IN	_	_	_	_	_
11	oral	_	_	JJ	_	_	_	_	_
12	suppression	_	_	NN	_	_	_	_	_
13	in	_	_	IN	_	_	_	_	_
14	tandem	_	_	NN	_	_	_	_	_
15	with	_	_	IN	_	_	_	_	_
16	surgical	_	_	JJ	_	_	_	_	_
17	debridement	_	_	NN	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	Infections	_	_	NNS	_	_	_	_	_
2	tend	_	_	VBP	_	_	_	_	_
3	to	_	_	TO	_	_	_	_	_
4	be	_	_	VB	_	_	_	_	_
5	recurrent	_	_	JJ	_	_	_	_	_
6	despite	_	_	IN	_	_	_	_	_
7	debridement	_	_	NN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	with	_	_	IN	_	_	_	_	_
10	Pseudomonas	_	_	NNP	_	_	_	_	_
11	infection	_	_	NN	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	particular	_	_	JJ	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	showing	_	_	VBG	_	_	_	_	_
16	a	_	_	DT	_	_	_	_	_
17	lower	_	_	JJR	_	_	_	_	_
18	success	_	_	NN	_	_	_	_	_
19	rate	_	_	NN	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	role	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	pump	_	_	NN	_	_	_	_	_
5	exchange	_	_	NN	_	_	_	_	_
6	is	_	_	VBZ	_	_	_	_	_
7	not	_	_	RB	_	_	_	_	_
8	clearly	_	_	RB	_	_	_	_	_
9	defined	_	_	VBN	_	_	_	_	_
10	.	_	_	.	_	_	_	_	_


1	One	_	_	CD	_	_	_	_	_
2	study	_	_	NN	_	_	_	_	_
3	noted	_	_	VBD	_	_	_	_	_
4	a	_	_	DT	_	_	_	_	_
5	particularly	_	_	RB	_	_	_	_	_
6	poor	_	_	JJ	_	_	_	_	_
7	prognosis	_	_	NN	_	_	_	_	_
8	with	_	_	IN	_	_	_	_	_
9	candidemia	_	_	NN	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	concomitant	_	_	JJ	_	_	_	_	_
12	presence	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	a	_	_	DT	_	_	_	_	_
15	cardiac-implanted	_	_	JJ	_	_	_	_	_
16	electronic	_	_	JJ	_	_	_	_	_
17	device	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	failure	_	_	NN	_	_	_	_	_
21	to	_	_	TO	_	_	_	_	_
22	remove	_	_	VB	_	_	_	_	_
23	the	_	_	DT	_	_	_	_	_
24	device	_	_	NN	_	_	_	_	_
25	during	_	_	IN	_	_	_	_	_
26	pump	_	_	NN	_	_	_	_	_
27	exchange	_	_	NN	_	_	_	_	_
28	was	_	_	VBD	_	_	_	_	_
29	associated	_	_	VBN	_	_	_	_	_
30	with	_	_	IN	_	_	_	_	_
31	poor	_	_	JJ	_	_	_	_	_
32	outcomes	_	_	NNS	_	_	_	_	_
33	in	_	_	IN	_	_	_	_	_
34	65	_	_	CD	_	_	_	_	_
35	%	_	_	NN	_	_	_	_	_
36	of	_	_	IN	_	_	_	_	_
37	patients	_	_	NNS	_	_	_	_	_
38	.	_	_	.	_	_	_	_	_


1	Some	_	_	DT	_	_	_	_	_
2	studies	_	_	NNS	_	_	_	_	_
3	have	_	_	VBP	_	_	_	_	_
4	shown	_	_	VBN	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	LVAD	_	_	NN	_	_	_	_	_
7	infections	_	_	NNS	_	_	_	_	_
8	adversely	_	_	RB	_	_	_	_	_
9	affect	_	_	VBP	_	_	_	_	_
10	survival	_	_	NN	_	_	_	_	_
11	after	_	_	IN	_	_	_	_	_
12	adjusting	_	_	VBG	_	_	_	_	_
13	for	_	_	IN	_	_	_	_	_
14	age	_	_	NN	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	comorbidities	_	_	NNS	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	One	_	_	CD	_	_	_	_	_
2	prospective	_	_	JJ	_	_	_	_	_
3	study	_	_	NN	_	_	_	_	_
4	showed	_	_	VBD	_	_	_	_	_
5	a	_	_	DT	_	_	_	_	_
6	22	_	_	CD	_	_	_	_	_
7	%	_	_	NN	_	_	_	_	_
8	overall	_	_	JJ	_	_	_	_	_
9	infection	_	_	NN	_	_	_	_	_
10	rate	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	LVADs	_	_	NNS	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	a	_	_	DT	_	_	_	_	_
15	5.6-times	_	_	NN	_	_	_	_	_
16	greater	_	_	JJR	_	_	_	_	_


1	1-year	_	_	JJ	_	_	_	_	_
2	mortality	_	_	NN	_	_	_	_	_
3	in	_	_	IN	_	_	_	_	_
4	patients	_	_	NNS	_	_	_	_	_
5	with	_	_	IN	_	_	_	_	_
6	infections	_	_	NNS	_	_	_	_	_
7	.	_	_	.	_	_	_	_	_


1	Besides	_	_	IN	_	_	_	_	_
2	mortality	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	LVAD	_	_	NN	_	_	_	_	_
5	infections	_	_	NNS	_	_	_	_	_
6	are	_	_	VBP	_	_	_	_	_
7	associated	_	_	VBN	_	_	_	_	_
8	with	_	_	IN	_	_	_	_	_
9	a	_	_	DT	_	_	_	_	_
10	greater	_	_	JJR	_	_	_	_	_
11	risk	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	pump	_	_	NN	_	_	_	_	_
14	thrombosis	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	bleeding	_	_	VBG	_	_	_	_	_
17	complications	_	_	NNS	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	prolonged	_	_	VBN	_	_	_	_	_
20	hospitalization	_	_	NN	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	need	_	_	NN	_	_	_	_	_
23	for	_	_	IN	_	_	_	_	_
24	pump	_	_	NN	_	_	_	_	_
25	exchange	_	_	NN	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	and	_	_	CC	_	_	_	_	_
28	failure	_	_	NN	_	_	_	_	_
29	to	_	_	TO	_	_	_	_	_
30	achieve	_	_	VB	_	_	_	_	_
31	transplantation	_	_	NN	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	Bloodstream	_	_	NN	_	_	_	_	_
2	infections	_	_	NNS	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	in	_	_	IN	_	_	_	_	_
5	particular	_	_	JJ	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	are	_	_	VBP	_	_	_	_	_
8	associated	_	_	VBN	_	_	_	_	_
9	with	_	_	IN	_	_	_	_	_
10	stroke	_	_	NN	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	increased	_	_	VBN	_	_	_	_	_
13	mortality	_	_	NN	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	Despite	_	_	IN	_	_	_	_	_
2	these	_	_	DT	_	_	_	_	_
3	risks	_	_	NNS	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	presence	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	an	_	_	DT	_	_	_	_	_
9	LVAD	_	_	NN	_	_	_	_	_
10	infection	_	_	NN	_	_	_	_	_
11	has	_	_	VBZ	_	_	_	_	_
12	not	_	_	RB	_	_	_	_	_
13	been	_	_	VBN	_	_	_	_	_
14	shown	_	_	VBN	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	have	_	_	VB	_	_	_	_	_
17	a	_	_	DT	_	_	_	_	_
18	negative	_	_	JJ	_	_	_	_	_
19	impact	_	_	NN	_	_	_	_	_
20	on	_	_	IN	_	_	_	_	_
21	post-transplant	_	_	JJ	_	_	_	_	_
22	outcomes	_	_	NNS	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	8.2	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Gastrointestinal	_	_	JJ	_	_	_	_	_
2	(	_	_	-LRB-	_	_	_	_	_
3	GI	_	_	NN	_	_	_	_	_
4	)	_	_	-RRB-	_	_	_	_	_
5	Bleed	_	_	NN	_	_	_	_	_


1	GI	_	_	NN	_	_	_	_	_
2	bleed	_	_	VBP	_	_	_	_	_
3	is	_	_	VBZ	_	_	_	_	_
4	one	_	_	CD	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	most	_	_	RBS	_	_	_	_	_
8	frequent	_	_	JJ	_	_	_	_	_
9	complications	_	_	NNS	_	_	_	_	_
10	after	_	_	IN	_	_	_	_	_
11	LVAD	_	_	NN	_	_	_	_	_
12	implant	_	_	NN	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	most	_	_	RBS	_	_	_	_	_
16	common	_	_	JJ	_	_	_	_	_
17	reason	_	_	NN	_	_	_	_	_
18	for	_	_	IN	_	_	_	_	_
19	hospital	_	_	NN	_	_	_	_	_
20	readmission	_	_	NN	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	triggered	_	_	VBN	_	_	_	_	_
4	by	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	use	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	antiplatelet	_	_	NN	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	anticoagulant	_	_	JJ	_	_	_	_	_
11	therapy	_	_	NN	_	_	_	_	_
12	.	_	_	.	_	_	_	_	_


1	Additionally	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	CF-LVADs	_	_	NNP	_	_	_	_	_
4	can	_	_	MD	_	_	_	_	_
5	cause	_	_	VB	_	_	_	_	_
6	acquired	_	_	VBN	_	_	_	_	_
7	von	_	_	NNP	_	_	_	_	_
8	Willebrand	_	_	NNP	_	_	_	_	_
9	factor	_	_	NN	_	_	_	_	_
10	deficiency	_	_	NN	_	_	_	_	_
11	due	_	_	JJ	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	high	_	_	JJ	_	_	_	_	_
15	shear	_	_	NN	_	_	_	_	_
16	stress	_	_	NN	_	_	_	_	_
17	imposed	_	_	VBN	_	_	_	_	_
18	by	_	_	IN	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	LVAD	_	_	NN	_	_	_	_	_
21	motor	_	_	NN	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	resulting	_	_	VBG	_	_	_	_	_
24	in	_	_	IN	_	_	_	_	_
25	breakdown	_	_	NN	_	_	_	_	_
26	of	_	_	IN	_	_	_	_	_
27	large	_	_	JJ	_	_	_	_	_
28	von	_	_	NNP	_	_	_	_	_
29	Willebrand	_	_	NNP	_	_	_	_	_
30	factor	_	_	NN	_	_	_	_	_
31	multimers	_	_	NNS	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	Also	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	continuous	_	_	JJ	_	_	_	_	_
4	flow	_	_	NN	_	_	_	_	_
5	physiology	_	_	NN	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	dysregulation	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	angiogenic	_	_	JJ	_	_	_	_	_
10	factors	_	_	NNS	_	_	_	_	_
11	have	_	_	VBP	_	_	_	_	_
12	been	_	_	VBN	_	_	_	_	_
13	shown	_	_	VBN	_	_	_	_	_
14	to	_	_	TO	_	_	_	_	_
15	lead	_	_	VB	_	_	_	_	_
16	to	_	_	TO	_	_	_	_	_
17	development	_	_	NN	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	arteriovenous	_	_	JJ	_	_	_	_	_
20	malformations	_	_	NNS	_	_	_	_	_
21	(	_	_	-LRB-	_	_	_	_	_
22	AVMs	_	_	NNS	_	_	_	_	_
23	)	_	_	-RRB-	_	_	_	_	_
24	in	_	_	IN	_	_	_	_	_
25	the	_	_	DT	_	_	_	_	_
26	gastrointestinal	_	_	JJ	_	_	_	_	_
27	tract	_	_	NN	_	_	_	_	_
28	,	_	_	,	_	_	_	_	_
29	nasopharynx	_	_	NN	_	_	_	_	_
30	,	_	_	,	_	_	_	_	_
31	brain	_	_	NN	_	_	_	_	_
32	,	_	_	,	_	_	_	_	_
33	and	_	_	CC	_	_	_	_	_
34	other	_	_	JJ	_	_	_	_	_
35	tissues	_	_	NNS	_	_	_	_	_
36	.	_	_	.	_	_	_	_	_

